Monday, 24 Feb 2020

Biologic/Novel Rx

Date Typesort ascending Title Save
20 Mar 2016 Social Tofacitinib meets primary endpoints in ulcerative colitis trials, achieving 16-18% remission rates https://t.co/mkWZTfz213
05 Nov 2017 Social RT @HealioRheum: Maternal #biologic use did not increase risk for opportunistic infections in #newborns https://t.co/1Iaj1awDK0 #ACR17 http…
28 Aug 2015 Social FDA issues guidance document- Nonproprietary Naming of Biological Products (includes biosimilars) http://t.co/lsLmHbQS0t
28 Dec 2017 Social This is the single best source on Biologics for Patients - Download the Patient Guide to Biologics from RheumNow. 6 pages of overview/comparisons; 5 biologic handouts https://t.co/D80f7I6Sr7
09 Nov 2018 Social Frankincense is derived from Boswellia plants. Boswellia serrata is an Ayurvedic purported to be anti-inflammatory; inhibits 5-lipoxygenase & possibly prostaglandins, Pilot studies in OA have shown significant pain relief and improved physical function https://t.co/OPxal73aIF
31 Jan 2017 Social @jhoronjeff @pfizer @US_FDA You missed the point - this is the kind of study that must be done to get an interchangeability indication
06 May 2016 Social A FREE Patient Guide to Biologic Use - available now at the RheumNow Website. 13 pages jammed with Patient Education https://t.co/f4BJvLu84N
29 Mar 2018 Social Large BSRBR study of Serious infections w/ biologics shows SI=5.51 per 100PY for all; tocilizumab was higher vs ETN (HR 1.22; 1.02 to 1.47) & certolizumab lower or equal to ETN. 30-day mortality following SI was 10.4% (95% CI 9.2% to 11.6%). https://t.co/h5BieShHpH
15 Feb 2017 Social Baricitinib (AKA Olumiant ) approved by EMA for use in EU for moderate-to-severe RA as monotherapy or combo w/ MTX https://t.co/7lFqrfL3fF
09 May 2019 Social Biologic Survival study from Japan- ANSWER study w/ 4466 courses in 2494 pts (2009-17). Efficacy Survival best for ABA, TCZ; worst for IFX & CZP. Toxicity Dropouts most in IFX & ADA, least ABA & CZP. Remission best w/ ETN & ABA, least w/ GLM, IFX. https://t.co/IgRDKLemjW
06 Jun 2016 Social Did you know that many (not all) biologics have latex? Dr. Dao writes how to Handle Latex Allergies w/ Biologics https://t.co/ToK3AmcAoX
03 May 2018 Social Sandoz biosimilar version of rituximab set back by a complete response letter from the FDA delaying development of their RTX biosimilar; same recent fate as Celltrions RTX biosimilar. https://t.co/EkikDMU1u8
14 Dec 2016 Social IL-33 a biomarker for RTX response - if RA pts are RF+ or CCP+; w/ detectable serum IL-33 & High IgG levels. https://t.co/meig18rSEX
02 Aug 2017 Social FDA Arthritis Advisory Panel votes against (12-2) approval of Sirukumab (IL6 inhib) for use in RA. FDA decision pending.
07 Mar 2017 Social Placebo outperforms Anakinra (22% vs 8%) in 50 patients with chronic Fatigue Syndrome. IL-1 inhibition fails in CFS https://t.co/c1PW8aglhU
13 Jun 2018 Social RT @FerreiraRJO: Excellent talk from Tracy French about how nurses can promote shared decision making with patients being proposed to switc…
23 Nov 2015 Social The new Etanercept biosimilar (SB4) in the EU is named Benepali, EMA recommended for RA, PsA, SpA & plaque psoriasis https://t.co/6tbvbO7cHY
08 Jun 2015 Social 967 pts Orencia RA registry (ORA) shows SIE rate 4.1/100PY. Predictive factors: age & # prior SIE or recurrent infx http://t.co/wrucZOW9HC
14 Apr 2017 Social Are there issues with BIOSIMILAR Safety, Switching or Cost? Patient survey: please vote 5 quick questions here https://t.co/ZvCVlif6Ij
27 Aug 2019 Social Olumiant (baricitinib) meets its primary endpoint in a phase 3 trial in moderate to severe atopic dermatitis (AD). The BREEZE-AD7 study is one of 5 phase 3 studies in the BREEZE-AD programme. https://t.co/FOO2bIzeVA